Literature DB >> 24894697

Positive enhancement integral values in dynamic contrast enhanced magnetic resonance imaging of breast carcinoma: ductal carcinoma in situ vs. invasive ductal carcinoma.

Mirjan Nadrljanski1, Ružica Maksimović2, Vesna Plešinac-Karapandžić3, Marina Nikitović3, Biljana Marković-Vasiljković2, Zorica Milošević3.   

Abstract

OBJECTIVES: The aim of this study was to contribute to the standardization of the numeric positive enhancement integral (PEI) values in breast parenchyma, ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) and to evaluate the significance of the difference in PEI values between IDC and parenchyma, DCIS and parenchyma and IDC and DCIS.
MATERIALS AND METHODS: In the prospective trial, we analyzed the dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of 60 consecutive patients with histologically confirmed unilateral DCIS (n=30) and IDC (n=30) and defined the PEI values (range; mean ± SD) for the lesions and the breast parenchyma. Tumor-to-non-tumor (T/NT) ratios were calculated for DCIS and IDC and compared. PEI color maps (PEICM) were created. The differences in PEI values between IDC and parenchyma and between DCIS and parenchyma were tested according to t-test. Analysis of variance (ANOVA) was used to test the differences between the mean PEI values of parenchyma, DCIS and IDC.
RESULTS: IDC showed highly statistically different PEI numeric values compared to breast parenchyma (748.7 ± 32.2 vs. 74.6 ± 17.0; p<0.0001). The same applied to the differences in the group of patients with DCIS (428.0 ± 25.0 vs. 66.0 ± 10.6; p<0.0001). The difference between IDC, DCIS and parenchyma were also considered highly statistically significant (p<0.0001) and so were the T/NT ratios for IDC and DCIS (10.1 ± 2.4 vs. 6.6 ± 1.4; p<0.0001).
CONCLUSIONS: PEI numeric values may contribute to differentiation between invasive and in situ breast carcinoma.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast; Breast neoplasms; Carcinoma; Ductal; Intraductal; Invasive; Magnetic resonance imaging; Noninfiltrating

Mesh:

Substances:

Year:  2014        PMID: 24894697     DOI: 10.1016/j.ejrad.2014.05.006

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Quantitative parameters of MRI and 18F-FDG PET/CT in the prediction of breast cancer prognosis and molecular type: an original study.

Authors:  Pavel Borisovich Gelezhe; Ivan Andreevich Blokhin; Damir Ildarovich Marapov; Sergey Pavlovich Morozov
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

2.  Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?

Authors:  Michael R Harowicz; Ashirbani Saha; Lars J Grimm; P Kelly Marcom; Jeffrey R Marks; E Shelley Hwang; Maciej A Mazurowski
Journal:  J Magn Reson Imaging       Date:  2017-02-09       Impact factor: 4.813

3.  Diagnostic value of dynamic contrast-enhanced magnetic resonance imaging in rectal cancer and its correlation with tumor differentiation.

Authors:  F U Shen; Jianping Lu; Luguang Chen; Zhen Wang; Yukun Chen
Journal:  Mol Clin Oncol       Date:  2016-02-03

4.  Quantitative discrimination between invasive ductal carcinomas and benign lesions based on semi-automatic analysis of time intensity curves from breast dynamic contrast enhanced MRI.

Authors:  Jiandong Yin; Jiawen Yang; Lu Han; Qiyong Guo; Wei Zhang
Journal:  J Exp Clin Cancer Res       Date:  2015-03-04

5.  Ductal Carcinoma in situ after Core Needle Biopsy: In Which Cases Is a Sentinel Node Biopsy Necessary?

Authors:  Robbert J H van Leeuwen; Birgitta Kortmann; Herman Rijna
Journal:  Breast Care (Basel)       Date:  2019-08-29       Impact factor: 2.860

6.  Predictive factors for the presence of invasive components in patients diagnosed with ductal carcinoma in situ based on preoperative biopsy.

Authors:  Kwan Ho Lee; Jeong Woo Han; Eun Young Kim; Ji Sup Yun; Yong Lai Park; Chan Heun Park
Journal:  BMC Cancer       Date:  2019-12-10       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.